ESC 365 - Safety and tolerability of diuretics withdrawal in patients with heart failure with reduced ejection fraction. REDICAE trial

Open Access

Safety and tolerability of diuretics withdrawal in patients with heart failure with reduced ejection fraction. REDICAE trial

Session: Late-breaking clinical trials in chronic heart failure

Topic: Pharmacotherapy

Speaker: Doctor J. Torres Zamudio (Cordoba, ES)

Event: Heart Failure 2025

Congress Presentation

Add to my library

About the speaker

Doctor Jesus Alberto Torres Zamudio

Reina Sofia University Hospital, Cordoba (Spain)

1 presentation

0 follower

5 more presentations in this session

Oral iron supplementation with ferric maltol improves iron deficiency anaemia in patients with chronic heart failure

Speaker: Professor T. Kempf (Hannover, DE)

Gene therapy for heart failure with preserved ejection fraction

Speaker: Doctor M. Fudim (Durham, US)

NAN-CS101: A first-in-human Phase 1 open-label dose-escalation study of AB-1002 gene therapy for the treatment of NYHA class III heart failure

Speaker: Doctor R. Hajjar (Boston, US)

Finerenone on arterial stiffness and cardiorenal biomarkers in patients with type 2 diabetes and chronic kidney disease: a randomized placebo-controlled mechanistic trial (FIVE-STAR)

Speaker: Professor A. Tanaka (Saga, JP)

Cardio-microcurrent device for chronic heart failure: results from the C-MIC II randomized controlled trial

Speaker: Professor S. Anker (Berlin, DE)

Access the full session

Late-breaking clinical trials in chronic heart failure

Speakers: Doctor J. Torres Zamudio, Professor T. Kempf, Doctor M. Fudim, Doctor R. Hajjar, Professor A. Tanaka...

About the event

Heart Failure 2025

17 May - 20 May 2025

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources

Explore sponsored resources